Arvinas (ARVN) Projected to Post Quarterly Earnings on Tuesday

Arvinas (NASDAQ:ARVN) will likely be announcing its earnings results before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of ($1.07) per share and revenue of $62.79 million for the quarter.

Arvinas Stock Performance

Shares of NASDAQ ARVN opened at $19.59 on Thursday. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The stock has a market cap of $1.35 billion, a PE ratio of -4.19 and a beta of 1.88. The stock has a fifty day moving average of $19.89 and a 200-day moving average of $23.70.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a report on Thursday, December 12th. BMO Capital Markets decreased their target price on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. BTIG Research assumed coverage on shares of Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price target for the company. Barclays reduced their price target on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday. Finally, HC Wainwright reiterated a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.45.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.